Company profile
Cullinan Therapeutics, Inc.
NASDAQ: CGEM · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
50DFH 56DQ 40GM —SS 57
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$219.9M
Employees
109
as of 2026-08-10
Market cap
$1.1B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$219.9M-$219.9M2025
Operating income-$241.6M-$241.6M2025
Total assets$448.4M$448.4M2025
Liabilities$39.6M$39.6M2025
Equity$408.7M$408.7M2025
Revenue trend
FY2021 – FY2022 · USD
FY21
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cullinan Therapeutics, Inc.’s revenue?
Cullinan Therapeutics, Inc. booked $0 in FY2022 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
SELLAS Life Sciences Group, Inc.50DRest Ez Inc.——Kardigan, Inc.——Design Therapeutics, Inc.55CMonopar Therapeutics Inc.59CAllogene Therapeutics, Inc.39DNeighbors
Middlesex →Key facts
CEONadim Ahmed
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: CGEM
Employees109
IPO date2021-01-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.